Combination of anti-PD-1 and anti-CTLA-4 with entinostat, a histone deacetylase inhibitor, decreased suppression by granulocytic MDSCs in the TME, significantly improving tumor-free survival in HER2 transgenic breast cancer mouse models [148]. Here, ERBB2 is linked to neoplasm.